The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Tesco Leads Gains After Barclays Update

Fri, 08th Jan 2016 08:30

LONDON (Alliance News) - UK shares opened higher Friday, helped by stabilised trading in China, with miners recovering some ground after two days of losses and supermarket Tesco the biggest gainer at the open, benefiting from an upgrade by Barclays.

The FTSE 100 index was up 0.5% at 5,986.57 points, the FTSE 250 was up 0.4% at 16,858.39, and the AIM All-Share was flat at 726.27. In Europe, the CAC 40 in Paris was down 0.1%, while the DAX 30 in Frankfurt was up 0.2%.

Tesco was the best blue-chip performer shortly after the open, up 3.5%, after Barclays upgraded the supermarket to Overweight from Equal Weight.

Broker ratings drove the movements in the blue-chip index in early trade, with outsourcer Capita up 1.7% after Nomura initiated it with a Buy recommendation and Marks & Spencer Group up 0.3% thanks to upgrades from S&P Capital IQ and Berenberg.

Intu Properties was at the bottom of the FTSE 100, down 2.1%, after Exane BNP cut the shopping centre developer and owner to Underperform from Neutral. Societe Generale also downgraded the group to Sell from Hold.

Miners were taking back some of the losses seen in the last two sessions. Glencore was up 2.3%, Rio Tinto up 1.4%, and Anglo American up 0.9%.

In the FTSE 250, Vectura Group was up 4.5% after the British-based pharmaceutical firm said it has completed a clinical trial for VR315 in the US, its generic therapy for asthma, and provided an update on one of its other developments.

VR315 is inhaled by patients using Vectura's proprietary dry powder inhaler and formulation technology, and the company said it can now confirm its partner for the VR315 and also the VR506 programmes in the US is Roxane Laboratories, a subsidiary of Boehringer Ingelheim.

In AIM, investment company Prospex Oil & Gas was up 23% after it said it agreed its first conditional acquisition since converting into an AIM investing company in April last year with a deal to buy a 49% stake in Hutton Poland.

Prospex will pay a total of GBP620,000 in cash for the 49% stake, with GBP130,000 to be paid initially and the balance to be deferred up to the end of August. Hutton has stakes in a number of exploration licences in Poland, including the Kolo licence area in the Polish Central Lowlands.

Confidence among investors was somewhat restored after China's central bank raised slightly the yuan reference rate and the country's securities regulator suspended its recently implemented circuit-breaker mechanism used to prevent further losses in its stock market.

In a statement late Thursday, the China Securities Regulatory Commission said the circuit breaker system would be halted starting Friday because it had produced "more negative impact than positive effects". The commission did not say how long the suspension would remain in place. It said it will undertake research and solicit opinions to improve the system.

The People's Bank of China raised Friday its guidance rate for the yuan for the first time in nine trading days, Reuters reported.

The PBOC set its daily midpoint rate for the yuan at 6.5636 per dollar prior to the market open, Reuters said. Under China's currency regime the yuan is allowed to deviate 2% either side of the midpoint. The rate was set at 6.5646 to the dollar on Thursday, compared to 6.5314 on Wednesday.

The Shanghai Composite ended up 2.3% on Friday, the Hang Seng index in Hong Kong closed up 0.6%, but the Japanese Nikkei 225 index finished down 0.4%.

Germany's exports and imports recovered in November from October, according to data from Destatis. Exports rose 0.4% in November from October, when it fell 1.3%. Likewise, imports grew 1.6% reversing a 3.2% drop in October. Economists had forecast exports to grow 0.5% and imports to improve 1.0%.

Another report from Destatis showed German industrial production decreased unexpectedly in November. Industrial production fell a seasonally 0.3% month-over-month in November, confounding economists' expectations for a 0.5% rise. In October, production grew 0.2%.

Still ahead in the economic calendar, UK's goods trade balance is due at 0930 GMT. In the US, nonfarm payrolls are due at 1330 GMT, and wholesale inventories are due at 1500 GMT.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more
4 Dec 2020 13:05

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

Read more
30 Nov 2020 09:53

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Read more
30 Nov 2020 08:06

Vectura signs asthma treatment deal with Kinaset

(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.

Read more
20 Nov 2020 08:34

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

Read more
19 Nov 2020 20:25

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
15 Sep 2020 17:22

Vectura Revenue Slips But Swings To First Half Profit

Vectura Revenue Slips But Swings To First Half Profit

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
2 Sep 2020 19:36

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

Read more
7 Jul 2020 16:35

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

Read more
9 Jun 2020 12:04

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

Read more
8 Jun 2020 15:00

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.